Siemens Healthineers


Testing firms are (again) back in favour

08/09/21 -"With the rise in Delta variant cases/risks in different parts of the world – especially in the US and Europe, testing firms are likely to witness re-emerging tailwinds. This has already begun ..."

Pages
63
Language
English
Published on
08/09/21
You may also be interested by these reports :
23/09/21
While the core business’s recovery momentum has sustained – reflecting in both the top-line and order book, cost headwinds due to higher supply ...

22/09/21
Orpea’s H1 results were broadly in line with analysts’ expectations and its real-estate portfolio continued enlarging. For FY21, the group reiterated ...

20/09/21
We used to see Fresenius (Buy, Germany) as a debt-financed acquisition-drive in the near certain business of public health. There is no such thing as ...

17/09/21
The material target price upgrade reflects Sonova’s sustainable technology leadership and strong fundamentals. Considering these important ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO